MacroGenics, Inc. Share Price

MacroGenics, Inc. Share Price

NASDAQ: MGNX | Micro Cap
$2.42
+$0.04 (1.89%) Last updated on 31 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

MacroGenics, Inc. Stock Performance

Open
$2.37
Prev. Close
$2.38
Circuit Range
N/A
Day Range
$2.24 - $2.44
Year Range
$1.29 - $5.07
Volume
70,358
Average Traded
$2.37

MacroGenics, Inc. Share Price Today

As of 31 October 2026, MacroGenics, Inc.'s share price is $2.42. The stock opened at $2.37, compared to its previous close of $2.38. During today's trading session, MacroGenics, Inc.'s share price traded between $2.24 and $2.44, with an average price of $2.34. Over the past 52 weeks, the stock has recorded a high of $5.07 and a low of $1.29. In terms of performance, MacroGenics, Inc.'s share price has declined by 21.17% over the last six months and is up 46.67% on a year-on-year basis.

MacroGenics, Inc. Share Price Chart

Line chart of the MacroGenics, Inc. price trend over the selected period. The price rose overall, ranging from 2.28 to 2.44, ending at 2.42.
$2.24$2.44
L
Show Current Price
H

MacroGenics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$152.84M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.23
Revenue (TTM)
$149.50B
Return On Equity (TTM)
-34.17%
Profit Margin
-49.91%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
16.05%

MacroGenics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$72.84$41.23$20.78$32.83
Net Profit$16.82-$14.16-$36.83$19.52
Net Profit Margin23.09%-34.34%-177.24%59.46%
Income ChangeN/A-184.19%-160.10%153.00%

MacroGenics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$151.94$58.75$149.96$149.50
Net Profit-$119.76-$9.06-$66.97-$74.62
Net Profit Margin-78.82%-15.42%-44.66%-49.91%
Income ChangeN/A92.43%-639.18%-11.42%

About MacroGenics, Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

MacroGenics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$3.78
$2.40
-37.61%
Sep 2026
$3.94
$3.85
-5.51%
Aug 2026
$3.72
$4.08
+10.42%
Jul 2026
$4.71
$3.69
-20.11%
Jun 2026
$4.12
$4.63
+10.65%
May 2026
$3.03
$4.18
+36.16%
Apr 2026
$2.95
$3.07
+6.41%
Mar 2026
$1.98
$2.88
+44.97%
Feb 2026
$1.83
$1.99
+8.45%
Jan 2026
$1.58
$1.83
+13.27%
Dec 2025
$1.48
$1.62
+5.19%
Nov 2025
$1.67
$1.54
-6.67%

MGNX Share Price FAQs